Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Melanoma Clinical Trial
Data on melanoma clinical trial published by researchers at University Hospital, Department of Dermatology
May 13th, 2008
Data detailed in 'Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate' have been presented. According to recent research published in the journal Melanoma Research, "Immunotherapy employs cytokines for modifying local inflammatory reactions. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to activate dendritic cells, macrophages, and granulocytes leading to clinical trials using GM-CSF-based cancer vaccine approaches." "Interleukin-2 (IL-2) is an...
Source: Cancer Weekly (2008-05-13)
|
